US Stock MarketDetailed Quotes
EQ Equillium
- 0.7098
- -0.0002-0.03%
Close Jul 9 16:00 ET
- 0.7092
- -0.0006-0.08%
Pre 08:45 ET
25.02MMarket Cap-2028P/E (TTM)
0.7199High0.6890Low92.57KVolume0.7011Open0.7100Pre Close65.34KTurnover0.52%Turnover RatioLossP/E (Static)35.25MShares3.250052wk High1.19P/B12.61MFloat Cap0.450052wk Low--Dividend TTM17.77MShs Float27.0500Historical High--Div YieldTTM4.35%Amplitude0.4500Historical Low0.7050Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Equillium Stock Forum
$Equillium(EQ.US)$
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads...
Equillium Announces Positive Topline Data From Phase 2 Study of EQ101 in Alopecia Areata
Equillium Inc: EQ101 Was Well Tolerated in Subjects With Alopecia Areata With No Serious Adverse Events Reported
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
NEWS
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium (Nasdaq: EQ) has surpassed the interim enrollment target in its Phase 3 EQUATOR study of itolizumab for acute graft-versus-host disease (aGVHD). Over 100 patients from more than 100 clinical trial sites in 12 countries are participating. Interim data will be reviewed by an independent data monitoring committee in Q3, which will trigger a thre...
No comment yet